China Medical GatewayLoading your healthcare gateway…

Shanghai GoBroad Cancer Hospital

Shanghai GoBroad Cancer Hospital — Shanghai

Hospital Profile

Shanghai Gaobo Cancer Hospital Affiliated to China Pharmaceutical University (Shanghai Gaobo Cancer Hospital) is a tertiary oncology specialty research hospital focused on solid tumors, funded and established by Gaobo Medical Group. The hospital is affiliated with China Pharmaceutical University and relies on the university's advantage in high-quality talent training and cutting-edge scientific research. It is based on public services for clinical research, aiming at the diagnosis and treatment of difficult and severe tumors, clinical research, and the industrial transformation of biomedicine and medical devices. The hospital is building a research-oriented hospital organization that aligns with international standards and accelerates the translation of innovative biomedical achievements.

Medical Milestones

• January 2024: Become an affiliated hospital of China Pharmaceutical University. • 2026/2027: Advancement of the Phase II project preparation (estimated to be put into use in 2026-2027, with about 700 beds available after combining Phase I and II).

Key Capabilities & Patient Care

Adhering to Gaobo Medical Group's philosophy of 'placing patient needs first,' we adopt the internationally advanced Multidisciplinary Care (MDC) model to provide comprehensive medical care. We have introduced a direct payment system for both urban medical insurance and commercial insurance. We offer a hotel-style healthcare environment along with one-stop medical guidance, care assistance, spiritual support, psychological comfort, patient mutual support, Heart-to-Heart Room, and other humanistic services. Regular events such as the 'Corner of Light' patient exchange meetings and holiday doctor-patient gatherings are also held.

Advanced Technology

Equipped with international advanced tumor diagnosis, detection, and treatment equipment such as PET-CT, 64-slice multi-layer CT, MRI, TOMO (helical tomotherapy system), and linear accelerator; building a comprehensive diagnosis and treatment support system covering all aspects and fields of tumor diagnosis and treatment. Relying on the group's academic resources and expert research teams, actively carrying out multiple tumor clinical trial projects. Data statistics: • Bed capacity: total construction area of 70,000 square meters, Phase I has 406 beds open, Phase II under preparation (combined bed capacity of about 700 beds for Phase I and II) • Number of departments: core business focuses on diagnosis and treatment of complex and severe tumors, clinical research, and integrated diagnostics; carrying out tumor surgery, radiotherapy, chemotherapy, and clinical trials; co-establishing a colorectal tumor diagnosis and treatment system with Fudan Cancer Hospital (2026) • Number of full-time physicians: not disclosed (relying on faculty from China Pharmaceutical University and national high-level talent) • Number of multi-site practicing / specially appointed experts: not disclosed; Fudan Cancer expert team to be stationed (2026); clinical research team led by Professor Li Jin (October 2025) • Annual outpatient volume: not disclosed • Surgical capacity: performing tumor surgery, radiotherapy, chemotherapy, and clinical trials; equipped with PET-CT, 64-slice CT, MRI, TOMO, linear accelerator, etc.; primary focus on clinical research • International certifications and qualifications: affiliated hospital of China Pharmaceutical University (since 2024); first research hospital in Shanghai Free Trade Zone (opened October 2023); positioned as a 'research hospital aligned with international standards'; direct settlement for medical insurance and commercial insurance • International services: positioned as a research hospital 'aligned with international standards'; exploring special import permits for overseas innovative drugs and medical devices (2024)

International Patient Services

Introduce a commercial insurance direct payment system, connect with international medical services, and create a high-quality medical experience for patients both domestically and internationally; build a research-oriented hospital organization that aligns with international standards, committed to improving cancer diagnosis and treatment levels worldwide.

Return to Home